MWNA
SAGE

Marshall Wace North America’s Sage Therapeutics SAGE Stock Holding History

Marshall Wace North America’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$9.48M Sell
214,034
-77,955
-27% -$3.57M 0.04% 367
2021
Q2 		$16.6M Sell
291,989
-169,712
-37% -$12M 0.07% 289
2021
Q1 		$34.6M Sell
461,701
-259,407
-36% -$21.3M 0.14% 170
2020
Q4 		$62.4M Buy
721,108
+299,169
+71% +$22.1M 0.28% 90
2020
Q3 		$25.8M Buy
+421,939
New +$21.4M 0.17% 156
2020
Q2 		– Sell
-9,482
Closed -$272K – 1438
2020
Q1 		$272K Buy
+9,482
New +$549K ﹤0.01% 862
2019
Q4 		– Sell
-167,060
Closed -$23.4M – 1555
2019
Q3 		$23.4M Buy
167,060
+40,843
+32% +$6.83M 0.13% 158
2019
Q2 		$23.1M Sell
126,217
-414,191
-77% -$70.7M 0.14% 139
2019
Q1 		$86M Buy
540,408
+53,704
+11% +$7.78M 0.61% 44
2018
Q4 		$46.6M Sell
486,704
-2,444
-0.5% -$280K 0.45% 64
2018
Q3 		$69.1M Sell
489,148
-38,468
-7% -$5.94M 0.47% 57
2018
Q2 		$82.6M Sell
527,616
-104,484
-17% -$16.4M 0.47% 46
2018
Q1 		$102M Sell
632,100
-4,917
-0.8% -$835K 0.51% 40
2017
Q4 		$105M Buy
637,017
+580,056
+1,018% +$56.2M 0.58% 32
2017
Q3 		$3.53M Sell
56,961
-285,277
-83% -$22.4M 0.02% 646
2017
Q2 		$27.4M Sell
342,238
-157,667
-32% -$11.4M 0.2% 131
2017
Q1 		$35.5M Buy
+499,905
New +$29.3M 0.28% 102

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Marshall Wace North America's SAGE Position: Q3 2021 in Review

Marshall Wace North America reduced its Sage Therapeutics (SAGE) stake by 27% in Q3 2021, selling an estimated $3.57M and leaving 214,034 shares worth $9.48M. The position accounts for 0.04% of the portfolio, ranked #367.

Marshall Wace North America first reported a position in SAGE in Q1 2017 and has held it in 17 quarters since. The position peaked at $105M in Q4 2017. 226 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Marshall Wace North America held 214,034 shares of Sage Therapeutics worth $9.48M as of Q3 2021.
  • Marshall Wace North America sold 77,955 Sage Therapeutics shares in Q3 2021, an estimated $3.57M.
  • Sage Therapeutics made up 0.04% of Marshall Wace North America's portfolio in Q3 2021, its #367 holding.
  • Marshall Wace North America first reported a position in Sage Therapeutics in Q1 2017 and has held it in 17 quarters since.
  • Marshall Wace North America's Sage Therapeutics position peaked at $105M in Q4 2017.
  • 226 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.